$97.74
4.244.53%
Ult. Agg.: Oct 5, 7:56 PM
$98.29
4.795.12%
10x Genomics (TXG) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
10x Genomics (TXG) ha pubblicato l'ultima guidance il agosto 6, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $610M - $630M per il periodo.
Rispetto alle previsioni precedenti, 10x Genomics ha modificato le sue previsioni di fatturato da un intervallo precedente di .
10x Genomics ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il 10x Genomics. 22
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.06 | $-0.10 | $-0.10 | $-0.15 |
| Actual | $-0.14 | $-0.10 | $-0.13 | $-0.22 |
| Surprise | -133.3% | 0.00% | -30.0% | -46.7% |
| Revenue | ||||
| Estimate | $146.7M | $146.4M | $159.1M | $142.5M |
| Actual | $151.0M | $150.8M | $166.0M | $149.0M |
| Surprise | +2.95% | +3.05% | +4.34% | +4.59% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.07 | $-0.04 | $-0.07 | $-0.12 |
| Revenue | ||||
| Consensus | $147.6M | $171.1M | — | — |
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.14 | $-0.06 | -133.3 % |
| Q1 | May 7, 2026 | $-0.10 | $-0.10 | 0.00 % |
| Q4 | Feb 12, 2026 | $-0.13 | $-0.10 | -30.0 % |
| Q3 | Nov 6, 2025 | $-0.22 | $-0.15 | -46.7 % |
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $151.00M | $146.68M | 2.95 % |
| Q1 | May 7, 2026 | $150.84M | $146.38M | 3.05 % |
| Q4 | Feb 12, 2026 | $166.03M | $159.13M | 4.34 % |
| Q3 | Nov 6, 2025 | $149.00M | $142.47M | 4.59 % |